About MIMESIS

A novel systems biology approach to develop preclinical assets from innovative drug discovery starting points inspired by viruses

Datasheet

Coordinator: ENYO Pharma SA
Call ID: H2020 – SME Instrument – Phase 2
Topic: Dedicated support to biotechnology SMEs closing the gap from lab to market
Total budget: 3.6 M€
EU contribution: 2.5 M€ (70%)
Start date: 01/11/2016
End date: 31/10/2018

EU flag

EU-funded Project

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement n° 739086-MIMESIS.

Outline

Access to new medicines targeting unmet medical need is a challenge for both the Pharmaceutical industry and the member states of the European union. For the last decade the pharmaceutical sector has faced fundamental dilemmas:

  • The average cost to develop a single drug has tripled
  • Patent expirations have reduced revenue from blockbuster drugs
  • Attrition in the drug development pipeline remains high
  • The rate of innovation in pharmaceutical development is low

Visuel_AproposIn this context, ENYO Pharma has developed an innovative systems biology based approach inspired by viruses to identify patentable chemistries directed at new human disease targets. In the last two years, the feasibility of this approach has been successfully demonstrated with the identification of 40 largely unexplored novel human targets against influenza virus, which resulted in the generation of lead series currently being developed by ENYO Pharma as a therapeutic.

Aims

The project MIMESIS aims:

  • To scale-up the number of drug discovery targets (not previously considered tractable to drug development) and preclinical assets
  • To scale-up the disease scope, in both infectious and non-infectious disease contexts
  • To initiate the deployment of the approach for possible licensing to the pharmaceutical industry

Thanks to the MIMESIS approach, ENYO Pharma will contribute to better access to medicines which will translate into higher pharmaceutical benefit to patients. The approach has not been used before in the pharmaceutical industry and is transferable to any human disease.

Schema_About_Mimesis_US